Article
- The EMBO Journal (1999) 18, 7002 - 7010
- doi:10.1093/emboj/18.24.7002
Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2
Nicolas Dumaz1 and David W. Meek1
- Biomedical Research Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
Correspondence to:
David W. Meek, E-mail: meek@icrf.icnet.uk
Received 20 August 1999; Accepted 25 October 1999; Revised 25 October 1999
Abstract
The p53 tumour suppressor protein is a labile transcription factor that is activated and stabilized in response to a wide range of cellular stresses, through a mechanism involving disruption of its interaction with MDM2, a negative regulatory partner. Induction of p53 by DNA damage additionally involves a series of phosphorylation and acetylation modifications, some of which are thought to regulate MDM2 binding. Here we report the effects of introducing mutations at several known or putative N-terminal phosphorylation sites on the transactivation function of p53. These studies highlight phosphorylation of Ser15, a key phosphorylation target during the p53 activation process, as being critical for p53-dependent transactivation. Biochemical data indicate that the mechanism by which phosphorylation of Ser15 stimulates p53-dependent transactivation occurs through increased binding to the p300 coactivator protein. The data also indicate that Ser15-dependent regulation of transactivation is independent of any involvement in modulating MDM2 binding, and that Ser15 phosphorylation alone is not sufficient to block the p53–MDM2 interaction.
Keywords:
- HDM2,
- p53,
- p300,
- phosphorylation,
- transactivation



